• SYEDA ADVIA SANOBAR
• Dr. K Sruthi
• Zaberunnisa

The design of enzyme inhibitors is one of the most captivating research topics in medicinal chemistry. Covalent inhibitors provide the opportunity of combining concepts of chemical reactivity and mechanisms of organic reactions with the structural features required for optimal molecular recognition in order to obtain the appropriate reactivity and selectivity profiles towards the desired enzyme target. A look at drug approvals in recent years suggests that covalent drugs will continue to make an impact on human health for years to come. The toxicity, high potencies and prolonged effects of covalent drugs result in less-frequent drug dosing. There are several examples of covalent inhibitors that are widely used drugs, including acetylsalicylic acid (an active ingredient of aspirin), orlistat (anti-obesity drug) and ampicillin (antibiotic). Overall, nearly 30% of the enzymes are irreversibly inhibited via covalent modification and highlights the therapeutic potential of covalent inhibitors.

Enzyme inhibitors, covalent inhibitors, toxicity, less-frequent drug dosing, acetyl salicylic acid, orlistat, and ampicillin.

"RATIONAL DESIGN OF COVALENTLY AND NON-COVALENTLY BINDING ENZYME INHIBITORS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 6, page no.164-173, June 2019, Available :http://www.jetir.org/papers/JETIR1907Q71.pdf

"RATIONAL DESIGN OF COVALENTLY AND NON-COVALENTLY BINDING ENZYME INHIBITORS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 6, page no. pp164-173, June 2019, Available at : http://www.jetir.org/papers/JETIR1907Q71.pdf